Perspective of use of antiviral peptides against influenza virus

Viruses

Volumn 7, Issue 10, 2015, Pages 5428-5442

  Skalickova, Sylvie ^a   Heger, Zbynek ^a,b   Krejcova, Ludmila ^a   Pekarik, Vladimir ^a   Bastl, Karel ^c   Janda, Jozef ^d   Kostolansky, Frantisek ^e   Vareckova, Eva ^e   Zitka, Ondrej ^a,b   Adam, Vojtech ^a,b   Kizek, Rene ^a,b  

^a MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^b BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^c Wool and Knitting Research Institute   (Czech Republic)

^d INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

^e INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Cationic peptides; Hemagglutinin; Influenza virus; Membrane fusion; Neuraminidase; Viral replication

Indexed keywords

AMANTADINE; CATHELICIDIN; INFLUENZA VIRUS HEMAGGLUTININ; MELITTIN; OSELTAMIVIR; POLYPEPTIDE ANTIBIOTIC AGENT; RIMANTADINE; SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; PEPTIDE;

ANTIVIRAL ACTIVITY; BACTERIAL INFECTION; CHEMICAL MODIFICATION; CYCLIZATION; IMMUNOPRECIPITATION; INFLUENZA VIRUS; PROTEIN DEGRADATION; REVIEW; VIRUS ATTACHMENT; VIRUS ENVELOPE; VIRUS REPLICATION; VIRUS TRANSCRIPTION; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PHYSIOLOGY; TRENDS; VIRUS ENTRY;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PEPTIDES; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84944901079     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7102883     Document Type: Review

References (98)

1. Wiesner, J.; Vilcinskas, A. Antimicrobial peptides the ancient arm of the human immune system. Virulence 2010, 1, 440-464. [CrossRef] [PubMed]
2. Mandal, S.M.; Silva, O.N.; Franco, O.L. Recombinant probiotics with antimicrobial peptides: Adual strategy to improve immune response in immunocompromised patients. Drug Discov. Today 2014, 19, 1045-1050. [CrossRef] [PubMed]
3. Nizet, V.; Ohtake, T.; Lauth, X.; Trowbridge, J.; Rudisill, J.; Dorschner, R.A.; Pestonjamasp, V.; Piraino, J.; Huttner, K.; Gallo, R.L. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001, 414, 454-457. [CrossRef] [PubMed]
4. Tew, G.N.; Clements, D.; Tang, H.Z.; Arnt, L.; Scott, R.W. Antimicrobial activity of an abiotic host defense peptide mimic. Biochim. Biophys. Acta 2006, 1758, 1387-1392. [CrossRef]
5. Silva, R.R.; Avelino, K.; Ribeiro, K.L.; Franco, O.L.; Oliveira, M.D.L.; Andrade, C.A.S. Optical and dielectric sensors based on an microbial peptides for microorganism diagnosis. Front. Microbiol. 2014, 5, 1-7. [CrossRef] [PubMed]
6. Hale, J.D.; Hancock, R.E. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev. Anti Infect. Ther. 2007, 5, 951-959. [CrossRef] [PubMed]
7. Hadley, E.B.; Hancock, R.E.W. Strategies for the discovery and advancement of novel cationic antimicrobial peptides. Curr. Top. Med. Chem. 2010, 10, 1872-1881. [CrossRef] [PubMed]
8. Fosgerau, K.; Hoffmann, T. Peptide therapeutics: Current status and future directions. Drug Discov. Today 2015, 20, 122-128. [CrossRef] [PubMed]
9. Sim, I.S. Potential of new drugs in the prophylaxis and therapy of influenza A virus-infections. Curr. Opin. Infect. Dis. 1989, 2, 411-414. [CrossRef]
10. Zumla, A.; Memish, Z.A.; Maeurer, M.; Bates, M.; Mwaba, P.; Al-Tawfiq, J.A.; Denning, D.W.; Hayden, F.G.; Hui, D.S. Emerging novel and antimicrobial-resistant respiratory tract infections: New drug development and therapeutic options. Lancet Infect. Dis. 2014, 14, 1136-1149. [CrossRef]
11. Berkhout, B.; Sanders, R.W. Molecular strategies to design an escape-proof antiviral therapy. Antivir. Res. 2011, 92, 7-14. [PubMed]
12. Wilson, J.C.; von Itzstein, M. Recent strategies in the search for new anti-influenza therapies. Curr. Drug Targets 2003, 4, 389-408. [CrossRef] [PubMed]
13. Air, G.M.; Brouillette, W.J. Influenza virus antiviral targets. Antiviral Res. 2009, 187-207.
14. Krol, E.; Rychowska, M.; Szewczyk, B. Antivirals-Current trends in fighting influenza. Acta Biochim. Pol. 2014, 61, 495-504. [PubMed]
15. Jitendra, P.K.; Bansal, S.; Banik, A. Noninvasive routes of proteins and peptides drug delivery. Indian J. Pharm. Sci. 2011, 73, 367-375. [PubMed]
16. Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Synthetic therapeutic peptides: Science and market. Drug Discov. Today 2010, 15, 40-56. [CrossRef] [PubMed]
17. Liderot, K.; Ahl, M.; Ozenci, V. Secondary bacterial infections in patients with seasonal influenza A and pandemic H1N1. Biomed. Res. Int. 2013, 2013, 1-6. [CrossRef] [PubMed]
18. Teixeira, V.; Feio, M.J.; Bastos, M. Role of lipids in the interaction of antimicrobial peptides with membranes. Prog. Lipid Res. 2012, 51, 149-177. [CrossRef] [PubMed]
19. Giangaspero, A.; Sandri, L.; Tossi, A. Amphipathic alpha helical antimicrobial peptides-A systematic study of the effects of structural and physical properties on biological activity. Eur. J. Biochem. 2001, 268, 5589-5600. [CrossRef] [PubMed]
20. Yin, L.M.; Edwards, M.A.; Li, J.; Yip, C.M.; Deber, C.M. Roles of hydrophobicity and charge distribution of cationic antimicrobial peptides in peptide-membrane interactions. J. Biol. Chem. 2012, 287, 7738-7745. [CrossRef] [PubMed]
21. Lee, N.;Walker, E.; Egerer, L.; Bunnell, B.A.; Mondal, D.; von Laer, D.; Braun, S.E. The therapeutic potential of secreted antiviral entry inhibitor (SAVE) peptides expressed by transduced MSCs to block HIV infection. Mol. Ther. 2014, 22, S183.
22. Pessi, A.; Ingallinella, P.; Bianchi, E.; Wang, Y.J.; Hrin, R.; Veneziano, M.; Bonelli, F.; Ketas, T.; Moore, J.; Miller, M. Dramatic increase of antiviral potency of an HIV peptide fusion inhibitor by targeting to lipid rafts via addition of a cholesterol group. Biopolymers 2009, 92, 302.
23. Abe, K.; Nozaki, A.; Tamura, K.; Ikeda, M.; Naka, K.; Dansako, H.; Hoshino, H.; Tanaka, K.; Kato, N. Tandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes. Microbiol. Immunol. 2007, 51, 117-125. [CrossRef] [PubMed]
24. Jenssen, H. Anti herpes simplex virus activity of lactoferrin/lactoferricin-An example of antiviral activity of antimicrobial protein/peptide. Cell. Mol. Life Sci. 2005, 62, 3002-3013. [CrossRef] [PubMed]
25. Jaishankar, D.; Yakoub, A.M.; Bogdanov, A.; Valyi-Nagy, T.; Shukla, D. Characterization of a proteolytically stable D-peptide that suppresses herpes simplex virus 1 infection: Implications for the development of entry-based antiviral therapy. J. Virol. 2015, 89, 1932-1938. [CrossRef] [PubMed]
26. Albericio, F.; Kruger, H.G. Therapeutic peptides foreword. Future Med. Chem. 2012, 4, 1527-1531. [CrossRef] [PubMed]
27. She, R.; Bao, H.; Zhang, Y.; Luo, D. Effect of rabbit sacculus rotundus antimicrobial peptides on serum antibody titers after vaccination with newcastle disease virus vaccine and avian influenza virus vaccine in chickens. Poult. Sci. 2008, 87, 81-86.
28. Pizzorno, A.; Abed, Y.; Boivin, G. Influenza drug resistance. Semin. Respir. Crit. Care Med. 2011, 32, 409-422. [CrossRef] [PubMed]
29. Mikulasova, A.; Vareckova, E.; Fodor, E. Transcription and replication of the influenza A virus genome. Acta Virol. 2000, 44, 273-282. [PubMed]
30. Das, K.; Aramini, J.M.; Ma, L.C.; Krug, R.M.; Arnold, E. Structures of influenza A proteins and insights into antiviral drug targets. Nat. Struct. Mol. Biol. 2010, 17, 530-538. [CrossRef] [PubMed]
31. Brunotte, L.; Flies, J.; Bolte, H.; Reuther, P.; Vreede, F.; Schwemmle, M. The nuclear export protein of H5N1 influenza A viruses recruits matrix 1 (M1) protein to the viral ribonucleoprotein to mediate nuclear export. J. Biol. Chem. 2014, 289, 20067-20077. [CrossRef] [PubMed]
32. Stubbs, T.M.; te Velthuis, A.J.W. The RNA-dependent RNA polymerase of the influenza A virus. Future Virol. 2014, 9, 863-876. [CrossRef] [PubMed]
33. Leser, G.P.; Lamb, R.A. Influenza virus assembly and budding in raft-derived microdomains: A quantitative analysis of the surface distribution of HA, NA and M2 proteins. Virology 2005, 342, 215-227. [CrossRef] [PubMed]
34. Takeda, M.; Leser, G.P.; Russell, C.J.; Lamb, R.A. Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion. Proc. Natl. Acad. Sci. USA 2003, 100, 14610-14617. [CrossRef] [PubMed]
35. Ma, K.; Wang, Y.J.; Wang, J.F. Influenza virus assembly and budding in lipid rafts. Prog. Biochem. Biophys. 2015, 42, 495-500.
36. Rossman, J.S.; Jing, X.H.; Leser, G.P.; Lamb, R.A. Influenza virus M2 protein mediates ESCRT-independent membrane scission. Cell 2010, 142, 902-913. [CrossRef] [PubMed]
37. Jones, J.C.; Turpin, E.A.; Bultmann, H.; Brandt, C.R.; Schultz-Cherry, S. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J. Virol. 2006, 80, 11960-11967. [CrossRef] [PubMed]
38. Jones, J.C.; Settles, E.W.; Brandt, C.R.; Schultz-Cherry, S. Identification of the minimal active sequence of an anti-influenza virus peptide. Antimicrob. Agents Chemother. 2011, 55, 1810-1813. [CrossRef] [PubMed]
39. Rajik, M.; Jahanshiri, F.; Omar, A.R.; Ideris, A.; Hassan, S.S.; Yusoff, K. Identification and characterisation of a novel anti-viral peptide against avian influenza virus H9N2. Virol. J. 2009, 6, 1-10. [CrossRef] [PubMed]
40. Nicol, M.Q.; Ligertwood, Y.; Bacon, M.N.; Dutia, B.M.; Nash, A.A. A novel family of peptides with potent activity against influenza A viruses. J. Gen. Virol. 2012, 93, 980-986. [CrossRef] [PubMed]
41. Matsubara, T.; Onishi, A.; Saito, T.; Shimada, A.; Inoue, H.; Taki, T.; Nagata, K.; Okahata, Y.; Sato, T. Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy. J. Med. Chem. 2010, 53, 4441-4449. [CrossRef] [PubMed]
42. Huttl, C.; Hettrich, C.; Miller, R.; Paulke, B.R.; Henklein, P.; Rawel, H.; Bier, F.F. Self-assembled peptide amphiphiles function as multivalent binder with increased hemagglutinin affinity. BMC Biotechnol. 2013, 13, 1-10. [CrossRef] [PubMed]
43. Cederlund, A.; Gudmundsson, G.H.; Agerberth, B. Antimicrobial peptides important in innate immunity. FEBS J. 2011, 278, 3942-3951. [CrossRef] [PubMed]
44. Hoffmann, J.; Schneider, C.; Heinbockel, L.; Brandenburg, K.; Reimer, R.; Gabriel, G.Anew class of synthetic anti-lipopolysaccharide peptides inhibits influenza A virus replication by blocking cellular attachment. Antivir. Res. 2014, 104, 23-33. [CrossRef] [PubMed]
45. Doss, M.; White, M.R.; Tecle, T.; Gantz, D.; Crouch, E.C.; Jung, G.; Ruchala, P.; Waring, A.J.; Lehrer, R.I.; Hartshorn, K.L. Interactions of α-, β-, and θ-defensins with influenza A virus and surfactant protein D. J. Immunol. 2009, 182, 7878-7887. [CrossRef] [PubMed]
46. Ammendolia, M.G.; Agamennone, M.; Pietrantoni, A.; Lannutti, F.; Siciliano, R.A.; de Giulio, B.; Amici, C.; Superti, F. Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus. Pathog. Glob. Health 2012, 106, 12-19. [CrossRef] [PubMed]
47. Li, Q.L.; Zhao, Z.H.; Zhou, D.H.; Chen, Y.Q.; Hong,W.; Cao, L.Y.; Yang, J.Y.; Zhang, Y.; Shi,W.; Cao, Z.J.; et al. Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. Peptides 2011, 32, 1518-1525. [CrossRef] [PubMed]
48. Tripathi, S.; Tecle, T.; Verma, A.; Crouch, E.; White, M.; Hartshorn, K.L. The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins. J. Gen. Virol. 2013, 94, 40-49. [CrossRef] [PubMed]
49. Ghanem, A.; Mayer, D.; Chase, G.; Tegge, W.; Frank, R.; Kochs, G.; Garcia-Sastre, A.; Schwemmle, M. Peptide-mediated interference with influenza A virus polymerase. J. Virol. 2007, 81, 7801-7804. [CrossRef] [PubMed]
50. Chase, G.; Wunderlich, K.; Reuther, P.; Schwemmle, M. Identification of influenza virus inhibitors which disrupt of viral polymerase protein-protein interactions. Methods 2011, 55, 188-191. [CrossRef] [PubMed]
51. Yang, J.; Li, M.M.; Shen, X.T.; Liu, S.W. Influenza A virus entry inhibitors targeting the hemagglutinin. Viruses 2013, 5, 352-373. [CrossRef] [PubMed]
52. Wunderlich, K.; Mayer, D.; Ranadheera, C.; Holler, A.S.; Manz, B.; Martin, A.; Chase, G.; Tegge, W.; Frank, R.; Kessler, U.; et al. Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. PLoS ONE 2009, 4, 1-10. [CrossRef] [PubMed]
53. Conti, G.; Magliani, W.; Conti, S.; Nencioni, L.; Sgarbanti, R.; Palamara, A.T.; Polonelli, L. Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection. Antimicrob. Agents Chemother. 2008, 52, 4331-4337. [CrossRef] [PubMed]
54. Salvatore, M.; Garcia-Sastre, A.; Ruchala, P.; Lehrer, R.I.; Chang, T.; Klotman, M.E. α-Defensin inhibits influenza virus replication by cell-mediated mechanism(s). J. Infect. Dis. 2007, 196, 835-843. [CrossRef] [PubMed]
55. Judd, A.K.; Sanchez, A.; Bucher, D.J.; Huffman, J.H.; Bailey, K.; Sidwell, R.W. In vivo anti-influenza virus activity of a zinc finger peptide. Antimicrob. Agents Chemother. 1997, 41, 687-692. [PubMed]
56. Nasser, E.H.; Judd, A.K.; Sanchez, A.; Anastasiou, D.; Bucher, D.J. Antiviral activity of influenza virus M1 zinc finger peptides. J. Virol. 1996, 70, 8639-8644. [PubMed]
57. Ahmed, C.M.; Dabelic, R.; Waiboci, L.W.; Jager, L.D.; Heron, L.L.; Johnson, H.M. SOCS-1 mimetics protect mice against lethal poxvirus infection: Identification of a novel endogenous antiviral system. J. Virol. 2009, 83, 1402-1415. [CrossRef] [PubMed]
58. Chang, Y.P.; Chu, Y.H. Using surface plasmon resonance to directly determine binding affinities of combinatorially selected cyclopeptides and their linear analogs to a streptavidin chip. Anal. Biochem. 2005, 340, 74-79. [CrossRef] [PubMed]
59. Udugamasooriya, D.G.; Spaller, M.R. Conformational constraint in protein ligand design and the inconsistency of binding entropy. Biopolymers 2008, 89, 653-667. [CrossRef] [PubMed]
60. Wang,W.; Cole, A.M.; Hong, T.;Waring, A.J.; Lehrer, R.I. Retrocyclin, an antiretroviral θ-defensin, is a lectin. J. Immunol. 2003, 170, 4708-4716. [CrossRef] [PubMed]
61. Doss, M.; White, M.R.; Tecle, T.; Hartshorn, K.L. Human defensins and LL-37 in mucosal immunity. J. Leukoc. Biol. 2010, 87, 79-92. [CrossRef] [PubMed]
62. Gutsmann, T.; Razquin-Olazaran, I.; Kowalski, I.; Kaconis, Y.; Howe, J.; Bartels, R.; Hornef, M.; Schurholz, T.; Rossle, M.; Sanchez-Gomez, S.; et al. New antiseptic peptides to protect against endotoxin-mediated shock. Antimicrob. Agents Chemother. 2010, 54, 3817-3824. [CrossRef] [PubMed]
63. Krepstakies, M.; Lucifora, J.; Nagel, C.H.; Zeisel, M.B.; Holstermann, B.; Hohenberg, H.; Kowalski, I.; Gutsmann, T.; Baumert, T.F.; Brandenburg, K.; et al. A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. J. Infect. Dis. 2012, 205, 1654-1664. [CrossRef] [PubMed]
64. Needham, B.D.; Trent, M.S. Fortifying the barrier: The impact of lipid a remodelling on bacterial pathogenesis. Nat. Rev. Microbiol. 2013, 11, 467-481. [CrossRef] [PubMed]
65. Anaya-Lopez, J.L.; Lopez-Meza, J.E.; Ochoa-Zarzosa, A. Bacterial resistance to cationic antimicrobial peptides. Crit. Rev. Microbiol. 2013, 39, 180-195. [CrossRef] [PubMed]
66. Mercer, D.K.; O'Neil, D.A. Peptides as the next generation of anti-infectives. Future Med. Chem. 2013, 5, 315-337. [CrossRef] [PubMed]
67. Marcos, J.F.; Gandia, M. Antimicrobial peptides: To membranes and beyond. Expert Opin. Drug Discov. 2009, 4, 659-671. [CrossRef] [PubMed]
68. Rajendran, L.; Knoelker, H.-J.; Simons, K. Subcellular targeting strategies for drug design and delivery. Nat. Rev. Drug Discov. 2010, 9, 29-42. [CrossRef] [PubMed]
69. Choi, K.-Y.G.; Mookherjee, N. Multiple immune-modulatory functions of cathelicidin host defense peptides. Front. Immun. 2012, 3, 149. [CrossRef] [PubMed]
70. Barlow, P.G.; Svoboda, P.; Mackellar, A.; Nash, A.A.; York, I.A.; Pohl, J.; Davidson, D.J.; Donis, R.O. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS ONE 2011, 6, 1-9. [CrossRef] [PubMed]
71. Dean, R.E.; O'Brien, L.M.; Thwaite, J.E.; Fox, M.A.; Atkins, H.; Ulaeto, D.O. A carpet-based mechanism for direct antimicrobial peptide activity against vaccinia virus membranes. Peptides 2010, 31, 1966-1972. [PubMed]
72. Pietrantoni, A.; Di Biase, A.M.; Tinari, A.; Marchetti, M.; Valenti, P.; Seganti, L.; Superti, F. Bovine lactoferrin inhibits adenovirus infection by interacting with viral structural polypeptides. Antimicrob. Agents Chemother. 2003, 47, 2688-2691. [PubMed]
73. Pietrantoni, A.; Dofrelli, E.; Tinari, A.; Ammendolia, M.G.; Puzelli, S.; Fabiani, C.; Donatelli, I.; Superti, F. Bovine lactoferrin inhibits influenza A virus induced programmed cell death in vitro. Biometals 2010, 23, 465-475. [CrossRef] [PubMed]
74. Balcao, V.M.; Costa, C.I.; Matos, C.M.; Moutinho, C.G.; Amorim, M.; Pintado, M.E.; Gomes, A.P.; Vila, M.M.; Teixeira, J.A. Nanoencapsulation of bovine lactoferrin for food and biopharmaceutical applications. Food Hydrocoll. 2013, 32, 425-431. [CrossRef]
75. Bibi, S.; Lattmann, E.; Mohammed, A.R.; Perrie, Y. Trigger release liposome systems: Local and remote controlled delivery? J. Microencapsul. 2012, 29, 262-276. [CrossRef] [PubMed]
76. Raghuraman, H.; Chattopadhyay, A. Melittin: A membrane-active peptide with diverse functions. Biosci. Rep. 2007, 27, 189-223. [CrossRef] [PubMed]
77. Lee, M.T.; Hung,W.C.; Chen, F.Y.; Huang, H.W. Mechanism and kinetics of pore formation in membranes by water-soluble amphipathic peptides. Proc. Natl. Acad. Sci. USA 2008, 105, 5087-5092. [CrossRef] [PubMed]
78. Ladokhin, A.S.; White, S.H. 'Detergent-like' permeabilization of anionic lipid vesicles by melittin. Biochim. Biophys. Acta 2001, 1514, 253-260. [CrossRef]
79. Zhang, N.Z.; Qi, J.X.; Feng, S.J.; Gao, F.; Liu, J.; Pan, X.C.; Chen, R.; Li, Q.R.; Chen, Z.S.; Li, X.Y.; et al. Crystal structure of swine major histocompatibility complex class I SLA-1*0401 and identification of 2009 pandemic swine-origin influenza A H1N1 virus cytotoxic t lymphocyte epitope peptides. J. Virol. 2011, 85, 11709-11724. [CrossRef] [PubMed]
80. Gordon-Grossman, M.; Zimmermann, H.; Wolf, S.G.; Shai, Y.; Goldfarb, D. Investigation of model membrane disruption mechanism by melittin using pulse electron paramagnetic resonance spectroscopy and cryogenic transmission electron microscopy. J. Phys. Chem. B 2012, 116, 179-188. [CrossRef] [PubMed]
81. Gordon-Grossman, M.; Gofman, Y.; Zimmermann, H.; Frydman, V.; Shai, Y.; Ben-Tal, N.; Goldfarb, D. A combined pulse EPR and monte carlo simulation study provides molecular insight on peptide-membrane interactions. J. Phys. Chem. B 2009, 113, 15128. [CrossRef]
82. Oren, Z.; Shai, Y. Mode of action of linear amphipathic α-helical antimicrobial peptides. Biopolymers 1998, 47, 451-463. [CrossRef]
83. Benachir, T.; Lafleur, M. Study of vesicle leakage induced by melittin. Biochim. Biophys. Acta 1995, 1235, 452-460. [CrossRef]
84. Lu, N.Y.; Yang, K.; Li, J.L.; Yuan, B.; Ma, Y.Q. Vesicle deposition and subsequent membrane-melittin interactions on different substrates: A QCM-D experiment. Biochim. Biophys. Acta 2013, 1828, 1918-1925. [CrossRef] [PubMed]
85. Li, W.Y.; Yang, X.F.; Jiang, Y.; Wang, B.N.; Yang, Y.; Jiang, Z.H.; Li, M.Y. Inhibition of influenza A virus replication by RNA interference targeted against the PB1 subunit of the RNA polymerase gene. Arch. Virol. 2011, 156, 1979-1987. [CrossRef] [PubMed]
86. Huet, S.; Avilov, S.V.; Ferbitz, L.; Daigle, N.; Cusack, S.; Ellenberg, J. Nuclear import and assembly of influenza A virus RNA polymerase studied in live cells by fluorescence cross-correlation spectroscopy. J. Virol. 2010, 84, 1254-1264. [CrossRef] [PubMed]
87. Manz, B.; Gotz, V.; Wunderlich, K.; Eisel, J.; Kirchmair, J.; Stech, J.; Stech, O.; Chase, G.; Frank, R.; Schwemmle, M. Disruption of the viral polymerase complex assembly as a novel approach to attenuate influenza A virus. J. Biol. Chem. 2011, 286, 8414-8424. [CrossRef] [PubMed]
88. Ruigrok, R.W.H.; Crepin, T.; Hart, D.J.; Cusack, S. Towards an atomic resolution understanding of the influenza virus replication machinery. Curr. Opin. Struct. Biol. 2010, 20, 104-113. [CrossRef] [PubMed]
89. Engler, A.C.; Shukla, A.; Puranam, S.; Buss, H.G.; Jreige, N.; Hammond, P.T. Effects of side group functionality and molecular weight on the activity of synthetic antimicrobial polypeptides. Biomacromolecules 2011, 12, 1666-1674. [CrossRef] [PubMed]
90. Ma, Q.Q.; Shan, A.S.; Dong, N.; Gu, Y.; Sun, W.Y.; Hu, W.N.; Feng, X.J. Cell selectivity and interaction with model membranes of Val/Arg-rich peptides. J. Pept. Sci. 2011, 17, 520-526. [CrossRef] [PubMed]
91. Fechter, P.; Mingay, L.; Sharps, J.; Chambers, A.; Fodor, E.; Brownlee, G.G. Two aromatic residues in the PB2 subunit of influenza A RNA polymerase are crucial for cap binding. J. Biol. Chem. 2003, 278, 20381-20388. [CrossRef] [PubMed]
92. Dias, A.; Bouvier, D.; Crepin, T.; McCarthy, A.A.; Hart, D.J.; Baudin, F.; Cusack, S.; Ruigrok, R.W.H. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 2009, 458, 914-918. [CrossRef] [PubMed]
93. Yuan, P.W.; Bartlam, M.; Lou, Z.Y.; Chen, S.D.; Zhou, J.; He, X.J.; Lv, Z.Y.; Ge, R.W.; Li, X.M.; Deng, T.; et al. Crystal structure of an avian influenza polymerase PA(n) reveals an endonuclease active site. Nature 2009, 458, 909-913. [CrossRef] [PubMed]
94. Zhu, X.Y.; Yu, W.L.; McBride, R.; Li, Y.; Chen, L.M.; Donis, R.O.; Tong, S.X.; Paulson, J.C.; Wilson, I.A. Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities. Proc. Natl. Acad. Sci. USA 2013, 110, 1458-1463. [CrossRef] [PubMed]
95. Stephens, C.; Kazan, K.; Goulter, K.C.; Maclean, D.J.; Manners, J.M. The mode of action of the plant antimicrobial peptide MiAMP1 differs from that of its structural homologue, the yeast killer toxin WmKT. FEMS Microbiol. Lett. 2005, 243, 205-210. [CrossRef] [PubMed]
96. Wilson, S.S.; Wiens, M.E.; Smith, J.G. Antiviral mechanisms of human defensins. J. Mol. Biol. 2013, 425, 4965-4980. [CrossRef] [PubMed]
97. Shah, R.; Chang, T.L. Defensins in viral infection. In Small Wonders: Peptides for Disease Control; American Chemical Society: Washington, DC, USA, 2012; pp. 137-171.
98. Mohan, T.; Sharma, C.; Bhat, A.A.; Rao, D.N. Modulation of HIV peptide antigen specific cellular immune response by synthetic α- and β-defensin peptides. Vaccine 2013, 31, 1707-1716. [CrossRef] [PubMed]